Activated Charcoal Use in Chronic Kidney Disease Patients

Recruiting now · Phase 2

Conditions studied: End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

In brief

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Key facts

Study ID

NCT06906874

Run by

Mansoura University

People needed

40

Starts

2025-08-01

Expected to finish

2025-11-01

Last updated by the study team

2025-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult aged ≥18 years with ESRD.
• Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.
• Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).

You may not qualify if…

• Severely malnourished (as diagnosed by the department's dietitian).
• Treated with overnight dialysis.
• Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL.

Where it is running

• Urology and Nephrology Center — Al Mansurah, Please Select, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.